Production of an antibiotic coating on a porous body comprises impregnation with a solution of gentamicin dodecyl sulfate or sulfonate (I) and evaporation of the solvent, where (I) has 1-5 dodecyl sulfate or sulfonate groups per gentamicin molecule. Independent claims are also included for: (1) a process for producing an antibiotic coating on a porous body, comprising impregnation with a solution ...

Novel dolasstatin derivatives of the formula (I): R<1>R<2>N-CHX-CO-A-B-D-E-(F)tK, in which R<1>, R<2>, A, B, D, E, F, K, X and t have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.

Novel dolasstatin derivatives of the formula (I): R<1>R<2>N-CHX-CO-A-B-D-E-(F)tK, in which R<1>, R<2>, A, B, D, E, F, K, X and t have the meanings stated in the description, and the preparation thereof are described. The novel substances have an antineoplastic effect.

Use of N-substituted pyrrolidone, imidazolidinone, oxazolidinone or thiazolidinone derivatives of formula (I), in all stereoisomer (or mixture) forms, or their salts for inhibiting the adhesion and/or migration of leukocytes or inhibiting VLA-4 receptors is new. W = R1-A-CR13 or R1A-CH=C; Y = CO, CS or CH2; Z = O, S or CH2 etc.; A = 1-6C alkylene, 3-7C cycloalkylene, (1-6C) alkylene-phenylene, or ...

The present invention relates to the preparation of novel vector systems which are generated by in-vitro recombination, using gene technology, of nucleic acids from foamy virus species and of exogenous nucleic acid, and are produced by suitable host cells or by recombinantly altered packaging cell lines. The recombinant preparation of particularly suitable packaging cell lines is likewise a consti...

The invention relates to 9-N-ethenyl derivatives of 9(S)-erythromycylamine, new semisynthetic antibiotics of the macrolide class of the general formula (I) wherein R<1> and R<2> are the same or different and represent nitryl, a carboxyl group of the formula COOR<3>, wherein R<3> represents a C1-C4 alkyl group, or a keto group of the formula COR<4>, wherein R<4> represents a C1-C4 alkyl grou...

The present invention relates to beta , beta -disubstituted derivatives of 9-deoxo-9a-N-ethenyl-9a-aza-9a-homoerythromycin A, new semisynthetic antibiotics of macrolide class of the general formula (I) wherein R<1> and R<2> are mutually the same or different and represent nitrile, carboxy group of the formula COOR<3>, wherein R<3> represents C1-C4 alkyl group, or keto group of the formu...

A subject of the invention is, as new chemical products, the compounds of formula (I)in which X represents a hydrogen atom or a halogen atom and Z represents a hydrogen atom or the remainder of an acid as well as their addition salts with acids. The compounds of formula (I) have antibiotic properties.

There is provided a feminine hygiene pad comprising a cover adjacent a capillarity fabric having regions of high and low capillarity, which is adjacent a retention layer. In a preferred embodiment, a creped spunbond layer is used as the cover material and a co-apertured intake/distribution layer and transfer delay layer are the capillarity fabric.Combining these improvements into an integrated abs...

The present invention relates to a process of disinfecting a hard-surface with a composition comprising cinnamon oil and/or an active thereof whereby disinfecting benefits are provided.

The invention relates to a method and device for effluent treatment, whereby the effluent (6) to be treated is biologically purified in a fixed-bed (1), in particular, a trickling filter and the output (12), from the fixed bed (1) is subjected to a dead-end membrane filtration (2) and the retained solids removed by back-flushing. Effluent (6) can, thus, be purified using a fixed-bed (1) to such a ...

Use of brivudine in the preparation of an oral pharmaceutical composition for the once-a-day treatment of herpes zoster infections or post-herpetic neuralgia. The amount of brivudine in each dose may be between 50 and 300 mg, preferably 125 mg. Use of a once daily dosage regimen improves patient compliance.

For meteredly dispensing a liquid over a period of several months from a container which can be stored over a long period of time, the need is for a container which is practically diffusion-tight and in which the liquid does not come into contact with the ambient atmosphere. The cartridge according to the invention is a three-shell container comprising a collapsible bag which contains the liquid, ...

This invention concerns a method and an apparatus for improving the efficiency of an open-cycle refrigeration process for LNG production by the employment of a liquid expander to recover energy associated with the flashing of a pressurized liquid stream and employing said recovered energy to compress the flashed vapor streams in the open cycle.

This invention concerns the use of the compounds of formula the N-oxides, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein A is CH, CR<4> or N; n is 0 to 4; Q is hydrogen or -NR<1>R<2>; R<1> and R<2> are selected from hydrogen, hydroxy, C1-12alkyl, C1-12alkyloxy, C1-12alkylcarbonyl, C1-12alkyloxycarbonyl, aryl, amino, mono- or di(C1-12a...

A method for the preparation of citalopram comprising reductive hydrolysis of a compound of Formula (IV) wherein R is a N,N-disubstituted amid group or an optionally substituted 4,5-dihydro-1,3-oxazol-2-yl group, and conversion of the resulting 5-formyl compound to citalopram.

An ophthalmic lens is disclosed which is suited for extended-wear periods of at least one day on the eye without a clinically significant amount of corneal swelling and without substantial wearer discomfort. The lens has a balance of oxygen permeability and ion or water permeability, with the ion or water permeability being sufficient to provide good on-eye movement, such that a good tear exchange...